Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity

Ryoma Nakao, Soichiro Kimura, Kimihiro Abe, Takehiro Yamaguchi, Eisuke Kuroda, Shigeto Hamaguchi, Kazuhiro Tateda, Yukino Ohki, Naoki Narisawa, Makoto Ohnishi, Yukihiro Akeda · 2025

Read Intranasal vaccination with probiotic Escherichia coli membrane vesicles displaying pneumococcal capsular polysaccharides elicits mucosal immunity by Ryoma Nakao, Soichiro Kimura, Kimihiro Abe, Takehiro Yamaguchi, Eisuke Kuroda, Shigeto Hamaguchi, Kazuhiro Tateda, Yukino Ohki, Naoki Narisawa, Makoto Ohnishi, Yukihiro Akeda (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12830806.txt.

Description

Ryoma Nakao and co-authors report a 2025 mouse study of a nose-spray vaccine against pneumococcal disease. The vaccine uses membrane vesicles from a helpful strain of Escherichia coli bacteria. The vesicles carry the sugar coat of a type 14 pneumococcus on their surface. The goal is guard at the nose and throat, where these germs first settle.

Mice given the spray made strong IgG in the blood, beating two licensed shots in the test. Only the spray route switched on IgA, the guard found in mucus, and it lasted through a year of checks. A vaccine that guards the airway lining could block infection early. More work is needed before human trials.

Catalog record

CREATORRyoma Nakao, Soichiro Kimura, Kimihiro Abe, Takehiro Yamaguchi, Eisuke Kuroda, Shigeto Hamaguchi, Kazuhiro Tateda, Yukino Ohki, Naoki Narisawa, Makoto Ohnishi, Yukihiro Akeda
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12830806

Browse the full library · About the Tower of Babel